InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
0
T+90 hit rate
67%
T+90 mean return
+3.9%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by KELLY RALPH DAVID, Director. Director active across 5 companies, notably Invesco Real Estate Income Trust Inc.. In total, 12 disclosures have been logged. Split: 1 buy · 0 sell. Total volume traded: €197k. History available since 21 July 2022. The latest transaction was filed on 1 April 2026 (J). Regulator: SEC (Form 4). The full history is free.
Declarations12 total
2,000 shares@ US$100.0046.7% of flowCommon Limited Liability Company UnitsSEC:0001193125-26-141788:0
10,000 shares@ US$20.00100.0% of flowCommon Limited Liability Company UnitsSEC:0001193125-26-141845:0
2,683.766 shares0Class E Common Stock, $0.01 par valueSEC:0001632674-25-000009:0
2,448.119 shares0Class E Common Stock, $0.01 par valueSEC:0001632674-25-000004:0
7,032 shares0Common StockSEC:0000950170-25-079846:0
2,180.93 shares0Class E Common Stock, $0.01 par valueSEC:0001632674-24-000007:0
2,414 shares0Common StockSEC:0000950170-24-067344:0
835.097 shares0Common Stock, $0.01 par valueSEC:0001632674-24-000003:0
747.152 shares0Common Stock, $0.01 par valueSEC:0001209191-23-055996:0
2,229 shares0Common StockSEC:0000899243-23-013385:0
2,000 shares@ US$100.00100.0% of flowCommon Limited Liability Company UnitsSEC:0001825265-22-000006:0
Ideal exit: 4 Apr 2023 (T+270)
2,078 shares0Common StockSEC:0000899243-22-026588:0
12 of 12 declarations
About KELLY RALPH DAVID
Ralph David Kelly is the General Counsel at Akero Therapeutics, Inc. He oversees legal and regulatory matters, ensuring the company's compliance. His expertise is essential for managing legal risks.
